» Articles » PMID: 29691378

Blockade of the C5a-C5aR Axis Alleviates Lung Damage in HDPP4-transgenic Mice Infected with MERS-CoV

Overview
Date 2018 Apr 26
PMID 29691378
Citations 152
Authors
Affiliations
Soon will be listed here.
Abstract

The pathogenesis of highly pathogenic Middle East respiratory syndrome coronavirus (MERS-CoV) remains poorly understood. In a previous study, we established an hDPP4-transgenic (hDPP4-Tg) mouse model in which MERS-CoV infection causes severe acute respiratory failure and high mortality accompanied by an elevated secretion of cytokines and chemokines. Since excessive complement activation is an important factor that contributes to acute lung injury after viral infection, in this study, we investigated the role of complement in MERS-CoV-induced lung damage. Our study showed that complement was excessively activated in MERS-CoV-infected hDPP4-Tg mice through observations of increased concentrations of the C5a and C5b-9 complement activation products in sera and lung tissues, respectively. Interestingly, blocking C5a production by targeting its receptor, C5aR, alleviated lung and spleen tissue damage and reduced inflammatory responses. More importantly, anti-C5aR antibody treatment led to decreased viral replication in lung tissues. Furthermore, compared with the sham treatment control, apoptosis of splenic cells was less pronounced in the splenic white pulp of treated mice, and greater number of proliferating splenic cells, particularly in the red pulp, was observed. These data indicate that (1) dysregulated host immune responses contribute to the severe outcome of MERS; (2) excessive complement activation, triggered by MERS-CoV infection, promote such dysregulation; and (3) blockade of the C5a-C5aR axis lead to the decreased tissue damage induced by MERS-CoV infection, as manifested by reduced apoptosis and T cell regeneration in the spleen. Therefore, the results of this study suggest a new strategy for clinical intervention and adjunctive treatment in MERS-CoV cases.

Citing Articles

Viral sepsis: diagnosis, clinical features, pathogenesis, and clinical considerations.

Xu J, Zhang W, Fu J, Fang X, Gao C, Li C Mil Med Res. 2024; 11(1):78.

PMID: 39676169 PMC: 11648306. DOI: 10.1186/s40779-024-00581-0.


Total plasma -glycomic signature of SARS-CoV-2 infection.

Bladergroen M, Pongracz T, Wang W, Nicolardi S, Arbous S, Roukens A iScience. 2024; 27(7):110374.

PMID: 39100929 PMC: 11294702. DOI: 10.1016/j.isci.2024.110374.


Enhancing prognostic prediction of invasive candidiasis among cancer patients with a serum C5a-based scoring model.

Li D, Wang L, Zhao Z, Bai C, Li X Support Care Cancer. 2024; 32(6):356.

PMID: 38750396 DOI: 10.1007/s00520-024-08567-3.


Emerging role of complement in COVID-19 and other respiratory virus diseases.

Xiao M, Ellsworth C, Qin X Cell Mol Life Sci. 2024; 81(1):94.

PMID: 38368584 PMC: 10874912. DOI: 10.1007/s00018-024-05157-8.


The complement cascade in lung injury and disease.

Detsika M, Palamaris K, Dimopoulou I, Kotanidou A, Orfanos S Respir Res. 2024; 25(1):20.

PMID: 38178176 PMC: 10768165. DOI: 10.1186/s12931-023-02657-2.


References
1.
den Haan J, Kraal G . Innate immune functions of macrophage subpopulations in the spleen. J Innate Immun. 2012; 4(5-6):437-45. PMC: 6741446. DOI: 10.1159/000335216. View

2.
Hui D, Memish Z, Zumla A . Severe acute respiratory syndrome vs. the Middle East respiratory syndrome. Curr Opin Pulm Med. 2014; 20(3):233-41. DOI: 10.1097/MCP.0000000000000046. View

3.
Grailer J, Fattahi F, Dick R, Zetoune F, Ward P . Cutting edge: critical role for C5aRs in the development of septic lymphopenia in mice. J Immunol. 2014; 194(3):868-72. PMC: 4297720. DOI: 10.4049/jimmunol.1401193. View

4.
Wong G, Li A, Ng P, Fok T . Severe acute respiratory syndrome in children. Pediatr Pulmonol. 2003; 36(4):261-6. PMC: 7168102. DOI: 10.1002/ppul.10367. View

5.
Zaki A, van Boheemen S, Bestebroer T, Osterhaus A, Fouchier R . Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012; 367(19):1814-20. DOI: 10.1056/NEJMoa1211721. View